March 2012
Monthly Prescribing Reference;Mar2012, Vol. 28 Issue 3, pA-7
The article offers information on the drug Bydureon for type II diabetes from Amylin Pharmaceuticals Inc. and Alkermes Inc. It further informs about the prescribing information of this drug and states that subcutaneous drug injection should be given to adults immediately after mixing two milligram once every seven days. It is also stated that this drug should not be used for treating type I diabetes or diabetic ketoacidosis and this drug is not recommended for use on children.


Related Articles

  • BYDUREON(tm) FDA Action Date Set for Jan 28 20112.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p237 

    The article reports that Eli Lilly & Co., Alkermes Inc., and Amylin Pharmaceuticals Inc., announced that the U.S. Food & Drug Administration (FDA) recognized the companies' BYDUREON (&x2122;) resubmission and the action date is on January 28, 2012. Christian Weyer, senior vice president of...

  • Bydureon to Treat Diabetes.  // MPR - Pharmacist's Edition;Spring2012, Vol. 6 Issue 1, pA:6 

    The article offers brief information on the Bydureon, an exenatide extended-release for injectable suspension indicated for type 2 diabetes mellitus, from Amylin Pharmaceuticals Inc. and Alkermes Inc.

  • Amylin's Bydureon NDA Data Held Back, FDA Says. Winter, Peter // BioWorld Today;6/27/2012, Vol. 23 Issue 124, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) requested Amylin Pharmaceuticals for additional information on the cardiovascular effects of Bydureon, a drug for the treatment of type II diabetes. Amylin issued a statement on FDA's agreement to use the data of Byetta, a...

  • Bydureon approval a shot across bow for Victoza. D. W. // Medical Marketing & Media;Mar2012, Vol. 47 Issue 3, p8 

    The article reports on the U.S. Food & Drug Administration's (FDA) approval of type 2 diabetes drug Bydureon, made by Amylin Pharmaceuticals Inc.

  • Can Byetta Be a Standalone Treatment for Type 2?  // Diabetes Health;Apr/May2008, Vol. 17 Issue 2, p25 

    The article considers the use of the drug Byetta as a standalone treatment for type 2 diabetes. As an anti-diabetes drug, Byetta, is used in conjunction with other medications, like metformin and TZD. But the drug's manufacturers, Amylin Pharmaceuticals and Eli Lilly, are planning to ask the...

  • Amylin, Novo Nordisk on GLP-1 Market Dominance.  // Bioworld Week;6/16/2008, Vol. 16 Issue 24, p3 

    The article reports on the market dominance of GLP-1 incretin mimetic drug produced by Amylin Pharmaceuticals Inc. in San Francisco, California. This drug, which is to treat Type II diabetes, was approved by the U.S. Food and Drug Administration (FDA). However, analysts predicted that Byetta...

  • Amylin Takes Hit After Two Deaths Are Linked to Byetta. Young, Donna // BioWorld Today;8/20/2008, Vol. 19 Issue 162, p1 

    The article reports that the stock price of Amylin Pharmaceuticals Inc. went down after its Byetta, its Type II diabetes product, got involved in the death of two patients. According to the U.S. Food and Drug Administration (FDA), the patients who were taking the drug died of acute pancreatitis...

  • Amylin, Icahn Continue Campaigns. Chambers, Heather // San Diego Business Journal;5/11/2009, Vol. 30 Issue 19, p6 

    The article reports on the move of San Diego diabetes drugmaker Amylin Pharmaceuticals Inc. to submit an application to the U.S. Food and Drug Administration (FDA) for its Byetta drug for type 2 diabetes in California. It discusses the importance of such move on the overall exenatide development...

  • Metformin.  // AHFS Consumer Medication Information;Jun2020, p1 

    Metformin is used alone or with other medications, including insulin, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Metformin helps to control the amount of glucose (sugar) in your blood. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics